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Abstract
Background: B lymphocyte stimulator (BLyS) is a member of the tumor necrosis factor superfamily of ligands that
mediates its action through three known receptors. BLyS has been shown to enhance the production of antibodies
against heterologous antigens when present at elevated concentrations, supporting an immunostimulatory role for
BLyS in vivo.
Methods: We constructed a fusion protein consisting of human BLyS and Pneumococcal Surface Adhesin A (PsaA)
and used this molecule to immunize mice. The immunostimulatory attributes mediated by BLyS in vivo were
evaluated by characterizing immune responses directed against PsaA.
Results: The PsaA-BLyS fusion protein was able to act as a co-stimulant for murine spleen cell proliferation
induced with F(ab’)2 fragments of anti-IgM in vitro in a fashion similar to recombinant BLyS, and immunization of
mice with the PsaA-BLyS fusion protein resulted in dramatically elevated serum antibodies specific for PsaA. Mice
immunized with PsaA admixed with recombinant BLyS exhibited only modest elevations in PsaA-specific responses
following two immunizations, while mice immunized twice with PsaA alone exhibited undetectable PsaA-specific
serum antibody responses. Sera obtained from PsaA-BLyS immunized mice exhibited high titers of IgG1, IgG2a,
IgG2b, and IgG3, but no IgA, while mice immunized with PsaA admixed with BLyS exhibited only elevated titers of
IgG1 following two immunizations. Splenocytes from PsaA-BLyS immunized mice exhibited elevated levels of
secretion of IL-2, IL-4 and IL-5, and a very modest but consistent elevation of IFN-g following in vitro stimulation
with PsaA. In contrast, mice immunized with either PsaA admixed with BLyS or PsaA alone exhibited modestly
elevated to absent PsaA-specific recall responses for the same cytokines. Mice deficient for one of the three
receptors for BLyS designated Transmembrane activator, calcium modulator, and cyclophilin ligand [CAML]
interactor (TACI) exhibited attenuated PsaA-specific serum antibody responses following immunization with PsaA-
BLyS relative to wild-type littermates. TACI-deficient mice also exhibited decreased responsiveness to a standard
pneumococcal conjugate vaccine.
Conclusion: This study identifies covalent attachment of BLyS as a highly effective adjuvant strategy that may yield
improved vaccines. In addition, this is the first report demonstrating an unexpected role for TACI in the elicitation
of antibodies by the PsaA-BLyS fusion protein.
Reviewers: This article was reviewed by Jonathan Yewdell, Rachel Gerstein, and Michael Cancro (nominated by
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B lymphocyte stimulator (BLyS, also designated TALL-1,
THANK, BAFF, TNFSF13b, and TNFSF20) is a member
of the tumor necrosis factor superfamily of ligands [1,2].
BLyS is expressed by activated T cells, activated macro-
phages, and dendritic cells [1,3,4] and has been
implicated in autoimmune disorders characterized by
the presence of pathological concentrations of self-anti-
gen-reactive antibodies, such as systemic lupus erythe-
matosus (SLE) [5] and rheumatoid arthritis (RA) [6].
Biological activity of BLyS is mediated via three recep-
tors present on B and T cells designated transmembrane
activator and calcium-modulator and cyclophilin ligand
[CAML] interactor (TACI), B-Cell Maturation Antigen
(BCMA) and BAFF Receptor (BR3 or BAFF-R) [7].
A functionally related molecule, designated APRIL
(A Proliferation Inducing Ligand) [8] has also been
described in mice and humans. APRIL binds to TACI
and BCMA but not to BAFF-R [9].
Our laboratory has been interested in attempting to
define mechanisms that influence the elicitation of anti-
body responses in the mammalian host. In this regard,
we have been interested in strategies that increase the
magnitude and diversity of antibody isotypes and cell-
mediated immune responses to antigens of interest,
while minimizing non-specific and frequently deleterious
i m m u n er e s p o n s e st h a tn o r m a l l ya c c o m p a n yt h eu s eo f
powerful adjuvants such as complete Freund’sa d j u v a n t
(CFA) and other bacterially derived products [10].
Therefore, BLyS was of considerable interest to us given
numerous reports in the literature that demonstrated
direct effects of BLyS on B cells. Transgenic mice that
over-express the human ortholog of BLyS exhibit
marked splenomegaly characterized by elevated numbers
of B cells, as well as elevated concentrations of serum
antibodies [11,12]. A similar, though transitory elevation
in serum immunoglobulin has also been observed fol-
lowing daily administration of purified BLyS to mice.
One of these studies demonstrated an elevation only
in serum IgM and IgA, but not IgG [1], while another
study noted elevation in the serum concentrations of
IgM, IgA, IgG and IgE [13]. Yet another study demon-
strated that daily administration of BLyS to mice immu-
nized with T-independent, or T-dependent antigens
resulted in substantial elevations of antigen-specific
serum antibody titers [14].
Collectively, these observations provided us the ratio-
nale to evaluate the ability of BLyS to act as a co-stimu-
lant for a T-dependent antibody response in vivo.T o
that end we constructed a genetic fusion of BLyS to the
test antigen PsaA (pneumococcal surface adhesin A)
[15]. PsaA is one of a number of highly conserved pro-
teins expressed by Streptococcus pneumoniae that are
currently being investigated for possible inclusion in a
third-generation protein-based pneumococcal vaccine
that can extend protective coverage to capsular sero-
types not represented in the currently licensed second-
generation polysaccharide-diphtheria toxoid conjugate
vaccines [16]. Immunity to PsaA has previously been
shown to be protective against pneumococcal infection,
and the development of strategies that can enhance the
immunogenicity of this, as well as other pneumococcal
protein antigens for possible use in future vaccines are
therefore of interest.
We reasoned that optimal stimulation of immune
responses might be achieved when the antigenic stimu-
lus (PsaA) and the co-stimulatory signal (BLyS) were
temporally and spatially linked. Our results indicate that
fusion of BLyS to the test pneumococcal antigen PsaA,
results in enhanced PsaA-specific cellular and antibody
responses, compared to immune responses elicited by
simple co-administration of BLyS together with PsaA or
PsaA alone in the absence of conventional adjuvants.
This study also reports an unexpected role for TACI in
the enhanced immunogenicity of the PsaA-BLyS fusion
in the immunized host.
Results
Expression, purification and characterization of
recombinant proteins
We constructed a series of plasmids that were used to
direct the expression of recombinant proteins in E. coli
(Figure 1A). Recombinant proteins containing BLyS
were purified from inclusion bodies following IPTG
induction of the relevant E. coli expression strains. PsaA
was purified from the soluble fraction of IPTG induced
E. coli lysates as previously described [17]. Evaluation of
the recombinant proteins by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE)
(Figure 1B) showed protein bands of the expected mole-
cular masses, and western blot with PsaA-specific anti-
sera (Figure 1C) confirmed the same. We used standard
proliferation assays to test the biological activity of
PsaA-BlyS. The results of 8 independent experiments
performed using splenocytes from BALB/c mice and
C3H/HeJ mice demonstrated that PsaA-BLyS was able
to enhance the viability of splenocytes when used alone
(Figure 1D), or when used in conjunction with F(ab’)2
anti IgM fragments as a B cell proliferation stimulus
(Figure 1E). These data confirmed that PsaA-BLyS
retained the stimulatory [12] and co-stimulatory [1,2]
activities previously described for BLyS. We were unable
to demonstrate any co-stimulatory activity of BLyS
when used in conjunction with suboptimal concentra-
tions of hamster anti-mouse CD3ε to stimulate T cell
proliferation. Previous experiments by others have
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Figure 1 Design, purification and characterization of recombinant proteins. A, Diagrammatic representation of recombinant proteins
purified from lysates of E. coli. Purified recombinant proteins were subjected to SDS-polyacrylamide gel electrophoresis and were detected by
direct staining with Coomassie blue (B), or by western blot using a PsaA-specific mouse anti-serum (C). The ability of BLyS-containing fusion
protein to enhance the viability of splenocytes from C3H/HeJ mice was tested in the absence (D) or presence of a suboptimal concentration of
polyclonal F(ab’)2 anti-μ (E).
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when BLyS is immobilized on culture plates, but not in
soluble form [18,19]. However, we were able to demon-
strate a potent stimulation of IFN-g secretion by spleno-
cytes in response to BLyS together with suboptimal
concentrations of anti-CD3ε, (data not shown). These
data are consistent with previous observations that BLyS
has T cell co-stimulatory activity [18-20].
Antibody responses elicited by immunization
Previous studies in our laboratory had established that
immunization of mice with PsaA at 100 pmol (3.7 μg
per mouse) in the absence of adjuvants resulted in the
elicitation of low to undetectable PsaA-specific antibo-
dies. We therefore chose this concentration of protein
for all immunization experiments with PsaA. Mice
immunized once with PsaA exhibited the expected low
to undetectable PsaA-specific serum antibody responses
(Figure 2A). Mice immunized once with the PsaA-BLyS
fusion protein (PsaA-BLyS) exhibited a robust PsaA-spe-
c i f i ca n t i b o d yr e s p o n s e( F i g u r e2 A ) .M i c ei m m u n i z e d
once with equimolar concentrations of PsaA and BLyS
(3.7 μg PsaA + 1.9 μg BLyS, corresponding to 100 pmol
of each) exhibited no elevation of PsaA specific serum
antibodies (Figure 2A). Antibody responses following a
second immunization of mice with the same antigen
combinations (PsaA, PsaA + BLyS, or PsaA-BLyS)
resulted in no PsaA-specific antibody response to PsaA
immunization, a modestly elevated PsaA-specific anti-
body response to PsaA + BLyS, and a far more robust
PsaA-specific response to PsaA-BLyS (Figure 2B).
Because mice with elevated levels of BLyS (BLyS
transgenic mice, [12,21]) tend to exhibit high titers of
circulating autoantibodies, we sought to evaluate the
effect of immunizations with BLyS on the levels of
autoantibodies in our experiments. To that end mice
immunized once (Figure 2C) or twice (Figure 2D) with
PsaA-BLyS, PsaA + BLyS or BLyS alone all failed to
exhibit elevated dsDNA-specific antibody responses. In
contrast, sera from non-immunized 6-month-old mice of
the autoimmune prone MRL/lpr strain (positive dsDNA
antibody control) exhibited high titers of dsDNA specific
antibodies. We also observed that mice immunized
once with PsaA-BLyS, PsaA + BLyS or BLyS alone exhib-
ited undetectable human BLyS-specific antibodies
(Figure 2E), while immunization twice with PsaA-BLyS
or PsaA + BLyS exhibited modest but detectable human
BLyS-specific antibody responses. Mice immunized twice
with PsaA alone or BLyS alone had undetectable human
BLyS-specific antibody responses (Figure 2F).
We subsequently used lipopolysaccharide (LPS) resis-
tant C3H/HeJ mice to simultaneously rule out an LPS
contamination effect on immune responses elicited by
the recombinant proteins, and to evaluate the ability of
a series of adjuvant formulations to prime for a primary
PsaA-specific antibody response. As shown in
Figure 2G, PsaA emulsified in Freund’sc o m p l e t ea d j u -
vant exhibited the most robust PsaA-specific antibody
responses, followed in order of effectiveness by the
PsaA-BLyS fusion protein, and PsaA admixed with CpG
containing oligodeoxynucleotides (CpG). The remaining
admixed combinations of PsaA + non-CpG containing
oligodeoxynucleotides (non-CpG) or PsaA + BLyS were
n o te f f e c t i v ea te l i c i t i n gap rimary PsaA-specific anti-
body response.
Evaluation of the IgG subclass distribution of PsaA
specific antibodies elicited by the different PsaA immu-
nization regiments are summarized in Figure 3A. These
data demonstrated that mice immunized twice with
PsaA, or PsaA + BLyS exhibited PsaA specific antibodies
exclusively of the IgG1 subclass. These results
contrasted markedly with the subclass distribution of
PsaA-BLyS immunized mice, which exhibited dramatic
elevations for IgG1, IgG2a, IgG2b and IgG3 subclasses.
Contrary to our expectations however, none of the
immunization regimens resulted in a PsaA-specific
serum IgA response (data not shown). Collectively these
data indicate that covalent linkage of BLyS to a test anti-
gen results in a highly immunogenic protein, which is
more effective at eliciting antibody responses than is the
test antigen merely admixed with BLyS.
Evaluation of PsaA-specific cellular recall responses
The marked elevations in PsaA-specific serum IgG2a
and IgG3 antibodies following immunization with
PsaA-BLyS led us to become interested in evaluating,
by ELISPOT, the cytokine secretion profiles of T cells
generated by exposure to BLyS at the time of initial
(primary) antigenic exposure. The data for cytokine
secretion assays are summarized in Figure 3B. Spleen
cells from mice primed with PsaA-BLyS responded
with the production of IL-2, IL-4, and IL-5 and very
modest but consistent IFN-g production. Mice primed
with PsaA or PsaA + BLyS exhibited only modest ele-
vations in IL-2, IL-4 and IL-5 in response to PsaA sti-
mulation, while the IFN-g responses were below those
observed for unstimulated control cultures. We used
ELISPOT to evaluate frequencies of PsaA-specific anti-
body secreting cells in the spleens of immunized mice.
PsaA-BLyS primed mice had larger numbers of PsaA-
specific ASC than mice primed with either PsaA or
PsaA + BLyS. Overall, evaluation of the cellular
responses supports the conclusion that fusion of PsaA
to BLyS resulted in a superior immunogen compared
to PsaA mixed with (but not covalently linked to)
BLyS, or to PsaA alone.
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Figure 2 Evaluation of antigen-specific and non-specific immunoglobulin responses. PsaA specific serum antibody responses were
determined for BALB/c mice immunized with the indicated recombinant proteins. Mice were immunized on weeks 0 and 3 and bled at weeks 2
and 5 for evaluation of primary (A, C and E) and secondary (B, D and F) antibody responses to PsaA, human BLyS and dsDNA, respectively, as
indicated. Serial dilutions of individual sera from 5 mice were tested for total (Ig) antibodies to specific antigens by ELISA and are plotted as
means ± SEM for 5 mice per group. G, Mice immunized twice with the indicated antigens as in Figure 2B were boosted with PsaA alone and
bled at week 9 for PsaA specific antibody responses. H, The relative immunogenicities of PsaA administered with various adjuvant formulations
was tested in C3H/HeJ mice. Groups of mice were immunized once and bled after 2 weeks for the evaluation of PsaA-specific total antibody
responses by ELISA. Data are presented as means ± SEM for 5 mice per group.
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Figure 3 Evaluation of antigen-specific immunoglobulin subclass and cytokine production. A, The IgG subclass distribution of PsaA-
specific antibodies was determined by ELISA for sera obtained from BALB/c mice at week 5 (following 2 immunizations as outlined in Figure 2).
Data are presented as means ± SEM for 5 mice per group. B, For ELISPOT assays, C3H/HeJ mice immunized with the indicated antigens at week
0, and boosted with PsaA alone at week 2. Splenocytes were prepared from individual mice at week 3 were stimulated with soluble PsaA for the
evaluation of PsaA-stimulated cytokine secreting cells, or with ELISPOT plate-immobilized PsaA for the enumeration of PsaA-specific antibody
secreting cells (ASC). The data for cytokine spots are combined from two experiments with 3 mice per group and the data for ASC are from one
experiment with 3 mice per group. Spots from individual mice and group means are shown.
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Page 6 of 18Evaluation of antibody responses in TACI-deficient mice
A previous report demonstrated that mice deficient in
expression of TACI, one of the 3 known BLyS receptors,
are unable to mount normal antibody responses to poly-
saccharide antigens (TI-2), while the antibody responses
to T-dependent (TD) protein antigens remain normal
[ 2 2 ] .W ei m m u n i z e dm i c ew i t hav a r i e t yo fa n t i g e n st o
characterize the antibody responses. Our data demon-
strate that TACI-deficient mice mount an attenuated
p r i m a r yP S - s p e c i f i ca n t i b o d yr e s p o n s ef o l l o w i n gi m m u -
nization with either purified type 3 PS (Figure 4A) or to
at y p e3P S - C R M 197 conjugate vaccine (Figure 4B).
TACI-deficient mice were able to mount normal anti-
body responses to the TD antigens KLH (Figure 4C)
and DT-B (Figure 4D). The primary serum antibody
responses were also essentially identical between TACI-
deficient and TACI-expressing littermates following a
single immunization with either KLH or DT-B (data not
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Figure 4 Evaluation of antigen-specific immunoglobulin responses in TACI-deficient mice. TACI-deficient mice (-/-), wild type (+/+) or
heterozygous (+/-) littermates were immunized with type 3 PS [PS] (A) or type 3 PS-CRM197 conjugate [Conj] (B) and evaluated for PS specific
serum antibodies by ELISA 2 weeks later. TACI-deficient or wild type littermates were immunized at weeks 0 and 2 with KLH [50 μg/mouse] (C),
or DT-B [2 μg/mouse] (D), and evaluated for specific antibody at week 4 by ELISA. For PsaA-specific serum antibody responses, TACI-deficient,
wild type, and heterozygous mice were immunized with 100 pmol of PsaA-BLyS fusion protein at week 0 (1°) and boosted with PsaA at week 3
(2°). Mice were bled at weeks 2 and 6 for the evaluation of primary (E) or secondary (F) PsaA-specific serum antibodies, respectively, by ELISA.
Data are presented as means ± SEM for sera from individual mice (4-5 mice per group). In A-D A405 values for preimmune sera (diluted 1:100)
were subtracted to generate specific absorbance for sera at 1:100 dilution.
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Page 7 of 18shown). Immunization of mice with PsaA-BLyS, fol-
lowed by a boost with PsaA alone revealed that TACI-
deficient mice failed to mount a robust PsaA-specific
serum antibody response following either the primary
immunization (Figure 4E) or a boost with PsaA
(Figure 4F). These results were interesting given our
expectation that PsaA-BLyS would be acting as a TD
antigen. In subsequent experiments, we demonstrated
that immunization of TACI-deficient mice with PsaA in
CFA followed by a boost with PsaA alone elicited PsaA-
specific antibody responses of equal magnitude to those
of TACI-sufficient wild type (TACI
+/+) or heterozygous
(TACI
+/-) mice (data not shown). These results support
our contention that that the defective antibody
responses to PsaA-BLyS by TACI-deficient mice point
to a specific requirement for TACI in the immune
response to PsaA-BLyS.
Discussion
BLyS has been the subject of extensive investigations
following its initial discovery and characterization as a B
lymphocyte stimulator. Many of the investigations have
focused on characterizing the role of BLyS in the gen-
eration and maintenance of B cell driven autoimmune
conditions such as systemic lupus erythematosus, and
rheumatoid arthritis. We undertook these experiments
to characterize the effects of BLyS on the induction of
cellular and humoral immune responses to a heterolo-
gous antigen. Our experiments suggest that BLyS is a
potent molecular adjuvant when administered to mice
in the form of a fusion protein conjugated to the target
antigen.
A mild adjuvant effect of BLyS was observed for mice
immunized with admixtures of BLyS and PsaA, and
moderate increases in PsaA-specific antibodies were
only evident following two immunizations with the
admixture. These PsaA-specific antibody responses were
further increased in the tertiary response following a
boost with PsaA alone. This enhancing effect of BLyS
coadministration on PsaA-specific antibody responses is
consistent with previous reports demonstrating the abil-
ity of BLyS to enhance the viability of suboptimally acti-
vated B cells [23], and to promote the survival of
plasmablasts [24]. We therefore suggest that enhanced
viability of PsaA-specific B cells/plasmablasts, rather
than other mechanisms, such as increased T cell help
was responsible for the observed difference in antibody
responses between PsaA + BLyS and PsaA. This notion
is indirectly supported by our ready demonstration of a
survival effect of BLyS on cell viability in vitro,a n d
because the PsaA-specific cytokine production elicited
by primary immunizations with PsaA + BLyS and PsaA
alone were similar. Although the tertiary antibody
responses following two immunizations with PsaA +
BLyS admixtures followed by PsaA alone were almost as
high as the tertiary antibody responses observed for two
immunizations with the PsaA-BLyS fusion protein fol-
lowed by PsaA alone, this response remained restricted
to the IgG1 subclass in the former cohort, while the lat-
ter cohort maintained the broad IgG subclass distribu-
tion observed for the secondary responses to PsaA-BLyS
(data not shown). Conjugation of BLyS to PsaA clearly
produced increased PsaA-specific responses over those
observed with PsaA and BLyS admixtures. We hypothe-
size that this resulted from efficient antigen capture via
BLyS specific receptors and subsequently improved anti-
gen presentation and T cell costimulation, as has been
shown for a model system utilizing a fusion of antigen
to IL-2 [25]. The broad IgG subclass distribution of IgG
responses elicited in response to immunization with the
fusion protein suggest that the modest increases
observed in antigen specific IFN-g production may have
been sufficient to drive the production PsaA-specific
IgG2a [26]. Alternatively, the efficient production of this
subclass and other IgG subclasses may have been driven
by BLyS mediated enhancement of cytokines not studied
here, such as IL-27 which has been shown to direct the
production of IgG2a in the absence of IFN-g [27].
Our results demonstrate that continuous administra-
tion of large amounts of BLyS are not required to
observe at least some enhancing effects on the immune
response to coadministered antigens, and suggests that
unconjugated BLyS may find utility as an adjuvant admi-
nistered with antigen as an admixed bolus, particularly
in situations where conjugation to target antigens of
interest is not feasible.
Our results demonstrate that the human ortholog of
BLyS (~85% amino acid identity and 94% similarity to
murine BLyS within the C-terminal extracellular
domain) [1] is biologically active in mice. We observed a
modest but reproducible anti-hBLyS response in mice
immunized twice with PsaA-BLyS, but we did not inves-
tigate whether these antibodies were capable of inhibit-
ing the biological activities of exogenous (human) or
endogenous (murine) BLyS. Future studies to address
the functional consequences of an anti-BLyS response
are of interest [28], wherein we would evaluate the abil-
i t yo fm u l t i p l ei m m u n i z a t i o n sw i t hP s a A - B L y St o
attenuate disease progression and autoantibody produc-
tion in an MRL/lpr mouse model of SLE or in a col-
lagen induced arthritis mouse model of RA [29,30].
Strategies aimed at attenuating the biological activity of
BLyS are justified, given the presence of increased levels
of endogenous BLyS in the circulation of MRL/lpr mice
[11], as well as the frequently observed elevation of
BLyS in RA and SLE patients [5,6,31].
Numerous studies have demonstrated B cell and T cell
co-stimulatory attributes of BLyS. Of the three receptors
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main receptor on B and T cells through which BLyS
exerts its co-stimulatory effects [19,32], while TACI has
been shown to be dispensable for the proliferation of
purified B cells in response to stimulation with BLyS
and anti-μ [33]. The majority of B cells, as well as a sub-
set of T cells express BAFF-R [19], while TACI is
expressed on a subset of B cells, including marginal
zone (MZ) B cells [19] and memory B cells [34]. Other
studies have shown that splenic B cells, which normally
express low levels of surface TACI can be induced to
express high levels of TACI by stimulation with anti-μ
[35] or toll-like receptor (TLR) ligands like CpG con-
taining oligodeoxynucleotides (CpG ODN) [36]. Investi-
gation of the expression of TACI on T cells has
produced conflicting results. One report has shown that
a polyclonal affinity purified antibody raised against
TACI binds to a subset of phorbol myristoyl acetate
(PMA)-activated human T cells [37], while another
study with TACI-specific monoclonal antibodies raised
against murine and human TACI failed to show TACI
expression on the surface of resting or activated murine
or human T cells, respectively [19]. The third receptor
for BLyS, BCMA appears to be expressed exclusively on
spleen and bone marrow plasma cells [34]. The initial
characterization of mice deficient in BCMA revealed no
overt abnormalities in the lymphoid cell compartment,
and these mice mounted normal antibody responses to
all antigens [38]. However, a more recent study has
demonstrated that BCMA-deficient mice exhibit a defect
in the survival and maintenance of long-lived bone mar-
row plasma cells [39].
Mice deficient in BAFF-R have reduced numbers of B
cells (~10% of BAFF-R intact littermates) and exhibit
attenuated responses to TD antigens, but close to nor-
mal responses to TI-2 antigens [40,41]. The phenotype
of BLyS deficient mice is even more severe than that of
BAFF-R deficient mice, and these mice exhibit impaired
immunoglobulin responses to both TI -2 and TD anti-
gens, in addition to ~10 fold reductions in total B cells
and baseline immunoglobulin concentrations, relative to
BLyS intact littermates [41,42]. By contrast, TACI-defi-
cient mice have increased numbers of B cells (~200% of
TACI intact littermates) and exhibit a defective response
to TI-2 antigens, while retaining the capacity to mount
normal responses to TD antigens [22,33]. On the basis
of these published observations, we might have expected
that BAFF-R would be the main receptor through which
BLyS (as a biologically active fusion partner to the T
dependent antigen PsaA) would exert its immunostimu-
latory effects. Our observation that the relatively potent
immunogenicity exhibited by PsaA-BLyS depended on
TACI expression was therefore unexpected. This obser-
vation suggests that the enhanced immunogenicity of
PsaA-BLyS was not simply the result of a carrier effect
wherein potentially immunogenic peptide fragments
from human BLyS that are not identical to those derived
from endogenous (murine) BLyS could provide addi-
tional linked T-cell-epitopes that could have contributed
to the immunogenicity of the fusion protein. A possible
explanation for our results is provided by recent article
that has reported very high levels of TACI expression
on murine bone marrow-derived dendritic cells (BMDC)
[30]. Expression of BAFF-R and BCMA was also
observed on these BMDC preparations, but at much
lower levels than observed for TACI. A separate study
has also reported TACI expression, but no BAFF-R
expression on human monocyte-derived dendritic cells
(DC) [43]. The discovery of TACI expression on DC is
key, because DC are widely acknowledged to be essential
to the priming of naïve T cells for a productive immune
response in vivo [44]. If the significant expression of
TACI on DC is confirmed for naturally arising DC
populations in the mammalian host, it would suggest
that the potent immunogenicity of PsaA-BLyS is primar-
ily facilitated by the binding of the fusion protein to DC
via TACI. In the absence of evidence for TACI expres-
sion by DC, we would be prompted to entertain the
hypothesis that B cells were the primary APC (by virtue
of their expression of TACI) responsible for the
enhanced immunogenicity of PsaA-BLyS. Although
there is evidence that antigen-specific B cells can serve
as effective APC for naïve CD4
+ T cells specific for the
same antigen [45], the large number of such antigen-
specific B cells that would be required in vivo to have
an impact makes this hypothesis less appealing.
The observation that T cells derived from a TACI-defi-
cient mouse strain (independently generated on a genetic
background similar to that used for the TACI-deficient
mice used in our experiments) respond to in vitro co-sti-
mulation with anti-CD3 and BLyS in a fashion similar to
wild type (TACI sufficient) littermates [19] suggests that
a deficit in T cell responses due to TACI ablation cannot
explain the attenuated immunogenicity of PsaA-BLyS in
our TACI-deficient mice. It is also curious that the
expected presence of PsaA-specific activated T cells
apparently failed to support a PsaA-specific antibody
response via other co-stimulatory pathways known to be
critical for T-dependent (TD) antibody responses, such
as the CD40-CD40L (CD154) axis [46].
In summary, our data are consistent with the hypothesis
that DC-mediated antigen presentation of PsaA-BLyS via
the binding of BLyS to TACI is essential for initiating
(priming) the PsaA-specific immune response, followed by
subsequent enhancement of this immune response via
BLyS mediated agonistic effects such as immunoglobulin
class switching [47], enhanced B and plasma cell survival
[14], and T cell co-stimulation [19,32].
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known receptors for BLyS (BAFF-R and BCMA) should
h e l pt od e f i n et h er e l a t i v ei m p o r t a n c eo fe a c hB L y S
receptor in the induction of immune responses by
PsaA-BLyS. Additionally, immunization of CD4
+ T cell-
deficient mice [48], and mice deficient in CD40L [49]
(which have defective antibody responses to TD antigens
but intact responses to TI antigens) with the PsaA-BLyS
fusion may shed more light on the T-dependence or
-independence of the response to PsaA-BLyS.
One of the main arguments against using BLyS as an
adjuvant is its propensity to promote autoantibody pro-
duction when present at elevated concentrations for
prolonged periods of time. The fact that we were unable
to demonstrate an elevation in dsDNA specific antibo-
dies following one or two immunizations with a BLyS
containing protein antigen would argue that transient
elevation in BLyS concentrations by itself might not be
sufficient to induce autoantibody production. Another
possibility is that the seemingly modest BLyS-specific
antibody response elicited by our constructs might have
been capable of neutralizing some of the biological
activities of BLyS and thereby attenuating autoantibody
production. Alternatively, the amounts of BLyS adminis-
tered in our experiments may have been insufficient to
drive self-sustaining autoantibody production. Consis-
tent with the latter view is the observation that while
daily injections of mice with up to 75μg of BLyS (3 mg/
kg) for 14 days resulted in elevated quantities of total
serum antibodies, these antibody levels returned to base-
line within 2 weeks following cessation of the BLyS
injections [13].
The utility of BLyS as a vaccine adjuvant has recently
been demonstrated in a murine model of pulmonary
Pseudomonas aeruginosa infection [50]. In this study
mice administered an adenoviral vector containing BLyS
coding sequences (adjuvant) along with a heat killed
whole cell P. aeruginosa vaccine (PA) exhibited higher
antibody concentrations than mice vaccinated with either
PA alone or PA and an empty adenoviral vector. BLyS
co-administration elicited elevated numbers of PA-speci-
fic CD4
+ T cells secreting IFN-g but not IL-4. The BLyS-
treated PA-vaccinated mice were solidly protected from
lethal pulmonary challenge with live P. aeruginosa, while
PA vaccinated mice not receiving BLyS were not signifi-
cantly protected. This protection correlated positively
with a substantial reduction of live bacteria in the lungs
of challenged mice, and was dependent on CD4
+ T cells,
as vaccination of mice deficient in CD4
+ T cells with
both PA and BLyS were unprotected. The critical contri-
bution of CD4
+ T cells to protection was further under-
scored by the observation that BLyS co-administration
elicited similar PA-specific antibodies in CD4
+ Tc e l l
intact and CD4
+ T cell-deficient mice.
Conclusions
There is need for more and improved vaccines that pro-
tect against pneumonias with a bacterial aetiology.
Although antibody-dependent mechanisms have long
been assumed to be exclusively responsible for protec-
tion against extracellular bacteria at mucosal surfaces,
several reports have recently demonstrated an antibody-
independent role for CD4
+ T cells in protective immu-
nity against respiratory inf e c t i o n s .T ot h a te n d ,I L - 1 7
[51] and IFN-g [52] production by CD4
+ T cells have
been shown to be protective. The protective action of
both IL-17 and IFN-g results from the ability of these
cytokines to direct the activation and infiltration of neu-
trophils to sites of infection for enhanced bacterial kill-
ing. As such, the development of protective vaccines
against mucosal infection must incorporate the capacity
for eliciting cell-mediated (CD4
+ T cell) responses char-
acterized by IFN-g and/or IL-17 production in response
to antigens from such pathogens.
This study suggests that covalent attachment of BLyS
can be an effective adjuvant strategy that might yield
improved vaccines. The elicitation of PsaA-specific anti-
bodies belonging to the IgG1, IgG2 and IgG3 subclasses,
as well as the modestly increased numbers of IFN-g
secreting cells supports the notion that BLyS effectively
facilitates the induction of a broad range of humoral
and cell-mediated immune responses. Another study has
also demonstrated that BLyS dramatically expands IL-17
secreting CD4
+ T cells [30]. Collectively, these data sug-
gest that the effectiveness of vaccines that protect
against bacterial pneumonias caused by gram-positive
(Streptococcus pneumoniae) and gram-negative (P. aeru-
ginosa) organisms can be enhanced by exploiting the
immunostimulatory attributes of BLyS as an adjuvant.
Methods
Mice and immunizations
Six- to eight-week old female BALB/c, C3H/HeJ, and
MRL/MpJ-Fas
lpr/J (MRL/lpr) mice were purchased from
The Jackson Laboratory, Bar Harbor, Maine. Mice defi-
cient in TACI have been previously described [22]. The
genetic background of the TACI knockout mouse col-
ony is equally 129SVJ and C57Bl/6 [22], and brother sis-
ter matings were used to generate TACI
+/+, TACI
+/- and
TACI
-/- genotypes. The genotyping of TACI mice was
performed by PCR using the primers MTS-1, 5’
CCTCAGGCCAGGAGCTTTTAGGGAGAA 3’;M T -
AS2: 5’ CCAGCATCCCCTCTGCTCTGGTTTTAT 3’;
and NEO-S1, 5’ CCTGGGTGGAGAGGCTTTTTGC
TTCCT 3’. Primers MT-S1 and MTAS2 amplify a 440
bp PCR fragment from the wild type locus and primers
Neo-S1 and MT-AS2 amplify a 300 bp PCR fragment
from the disrupted TACI locus. The PCR conditions
used were one cycle at 95°C for 5 minutes, followed by
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1 min.) followed by a 10 min. cycle at 72°C. Amplified
products were electrophoresed through 1.2% Tris-
borate-EDTA buffered agarose gels, and stained with
ethidium bromide to visualize the amplified PCR
products.
All mice were housed under specific pathogen-free con-
ditions, with sterile food and water ad libitum. The Case
Western Reserve University Institutional Animal Care and
Use Committee approved all animal experiments.
For immunizations, groups of 5-6 mice were injected
intraperitoneally (i.p.) with antigens in 100 μlo fp h o s -
phate buffered saline (PBS). Mice were immunized with
100 pmol of recombinant antigens (PsaA, PsaA-BLyS,
BLyS, or equimolar mixtures of BLyS and PsaA) unless
otherwise indicated. In some experiments synthetic
phosphorothioate CpG containing oligodeoxynucleotide
(ODN) 1826 (5’ TCCATGACGTTCCTGACGTT 3’)
and non-CpG ODN 1972 (5’ TCCAGGACTTCTCT-
CAGGTT 3’) (gifts from Clifford Harding, Case Western
Reserve University) were used as adjuvant and control
ODNs, respectively at 50 μga d m i x e dw i t h1 0 0p m o l
PsaA in PBS per mouse. Complete Freund’sA d j u v a n t
(CFA; Sigma) was used as a 1:1 (v/v) emulsion with 100
pmol PsaA in PBS. Sera were prepared from blood col-
lected from mice via the tail vein and were stored at
-20°C until used for assays.
Plasmid construction and recombinant protein
purification
A plasmid encoding the soluble extra-cellular domain of
human BLyS was constructed by cloning a PCR ampli-
fied fragment of BLyS (amino acids 140-285) into
pET27b+ (Novagen) at the NcoIa n dXhoI sites. A plas-
mid encoding PsaA fused to the N-Terminus of soluble
BLyS was made by ligating the PsaA coding sequence
from the previously described p29-psaA plasmid [17]
into pET27-BLyS at the XbaIa n dHindIII sites. This
action replaced the signal peptide sequence in pET27-
BLyS with an S-Tag sequence. Recombinant proteins
were expressed and purified from lysates of the E. coli
expression strain BL21(DE3) (Novagen) by metal affinity
chromatography according to the manufacturers instruc-
tions (Novagen). The purified recombinant proteins
were dialyzed extensively against PBS containing 50 mM
Tris (pH 8.8). Protein concentrations were estimated
using a Bradford kit (Bio-Rad) and filter sterilized using
0.22 μm syringe filters (Millipore) prior to storage at
4°C. Endotoxin (LPS) contamination of recombinant
proteins was measured using a limulus amebocyte lysate
kit (LAL; Sigma) and were determined to be below the
level of detection (<50 Endotoxin units/ml). Additional
recombinant proteins used in these experiments were
non-lipidated putative protease maturation protein A
(PpmA; amino acids 21-309) of Streptococcus pneumo-
niae [53], and the non-toxic B fragment of diphtheria
toxin (DT-B, amino acids 202-535) [54]. Each was
cloned as a PCR amplified gene fragment into pET29b+
plasmid (Novagen) at NcoIa n dXhoI. These recombi-
nant proteins were expressed and purified from lysates
of recombinant E. coli as described above. Additionally,
keyhole limpet hemocyanin (KLH) purchased from
Sigma was used as a T-dependent antigen, and type 3
capsular polysaccharide (PS) from Streptococcus pneu-
moniae was used as a Type 2 T-independent antigen.
A glycoconjugate vaccine consisting of Type 3 PS cova-
lently linked to diphtheria toxoid (CRM197)w a sag i f to f
Dr. Ron Eby, Wyeth Vaccines.
Gel electrophoresis and Western blot for detection of
recombinant proteins
Recombinant proteins were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
under reducing conditions, and either stained directly
with Coomassie blue to visualize the proteins, or else
electrophoretically transferred to polyvinylidene difluor-
ide (PVDF) membranes (Bio-Rad, Hercules, CA) for pro-
tein detection by Western blot. The PVDF membranes
were reacted first with polyclonal mouse PsaA-specific
antisera, followed by incubation with alkaline phospha-
tase conjugated goat anti-mouse IgG. Positively reacting
protein bands were visualized by incubation in
5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazo-
lium (BCIP-NBT) chromogenic phosphatase substrate
(Sigma).
In vitro assay for BLyS bioactivity
Standard co-stimulation assays were performed to
demonstrate that the recombinant BLyS proteins pro-
duced for these experiments retained their ability to sti-
mulate B cells. Splenocytes from C3H/HeJ mice or
BALB/c mice were seeded into individual wells of a 96
well plate at 5 × 10
5 cells per well in RPMI supplemen-
ted with 10% fetal bovine serum (RPMI-10). Serial dilu-
tions of recombinant PsaA or PsaA-BLyS in RPMI-10
and a F(ab’)2 fragment of goat anti-mouse IgM (μ heavy
chain specific) in RPMI-10 were added to wells in tripli-
cate. The final volume was 200 μl per well. Plates were
incubated for 48 hours at 37°C in 5% CO2.A l a m a rb l u e
(Accumed; 20 μl per well) was added at 48 hrs, and
plates were incubated at 37°C for an additional 20-
24 hours. Absorbances at 570 nm and 600 nm were
read using a Bio-Rad plate reader. Data are presented as
specific absorbance (A570-A600). Increased absorbance is
directly proportional to the amount of reduction of Ala-
mar blue in stimulated cultures, which in turn is directly
proportional to the number of viable cells in each well
[55]. Recombinant PsaA and PsaA-BLyS were tested at
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(ab’)2 anti-μ or control goat F(ab’)2 were each used at 1
μg/ml. Similar T cell co-stimulation assays were
performed using recombinant BLyS and a hamster anti-
mouse CD3ε monoclonal antibody (Southern Biotech-
nology Associates, Birmingham, AL) as the primary T
cell stimulus. An isotype-matched hamster antibody of
irrelevant specificity from the same vendor was used as
a control in these assays. The Alamar blue procedure
described above was used for the evaluation of T cell
proliferation by splenocytes from BALB/c and C3H/HeJ
mice.
Characterization of antibody responses
ELISA was used to characterize PsaA-specific antibody
responses in mice immunized with PsaA, PsaA and
BLyS or PsaA-BLyS fusion protein generated in these
experiments. Briefly, 96-well plates (Immulon I, Dyna-
tech, Chantilly, VA) were coated with recombinant PsaA
(2 μg/ml, 100 μl per well) overnight at 4°C. Serial dilu-
tions of sera were added to the wells in duplicate. Alka-
line phosphatase (AP)-conjugated antibodies specific for
murine immunoglobulins were used as the secondary
reagent. The plates were developed by adding p-nitro-
phenyl phosphate (Sigma) and read at 405 nm using a
spectrophotometer (Molecular Devices, Inc.). Relative
antibody concentrations were determined by performing
ELISA on serial dilutions of individual sera. AP-conju-
gated antibodies specific for murine immunoglobulins
(Ig) were purchased from Southern Biotechnology
Associates, Birmingham, AL.
To test for the elicitation of human BLyS-specific anti-
bodies following immunization of mice with the BLyS-
containing recombinant proteins and mixtures described
above, ELISA assays were performed as described above,
except that the microtiter plates were coated with
recombinant BLyS (2 μg/ml, 100 μl/well).
To test for the elicitation of autoantibodies in mice
that had received BLyS or PsaA-BLyS as part of the
immunization regiment, we performed ELISA assays to
detect the presence of double-stranded (ds) DNA speci-
fic antibodies. Immunlon I plates were coated with calf
thymus DNA (Sigma) at 2.5 μg/ml, 100 μl per well over-
night at 4°C. Plates were washed and incubated with
serial dilutions of antisera from immunized mice. Sera
from 6-month-old MRL/MpJ-Fas
lpr/J (MRL/lpr) mice
were included as positive (dsDNA reactive) controls,
and sera from 3-month-old BALB/c mice were included
as negative (dsDNA non-reactive) controls. Following
washes, bound antibodies were detected using AP-
conjugated goat anti-mouse Ig, after incubation with
p-nitrophenyl phosphate as described above.
Antibodies specific for KLH and DT-B were assessed
by ELISA in the sera of KLH and DT-B immunized
mice using Immulon 1 microtiter plates coated with
KLH (10 μg/ml, 100 μl per well) or DT-B (2 μg/ml, 100
μl per well), and were developed as described for PsaA-
specific antibody detection. Type 3 PS-specific antibo-
dies elicited in response to immunization with type 3 PS
or its CRM197 conjugate were assessed by ELISA using
Polysorp plates (Nunc, Roskilde, Denmark) coated with
type 3 PS (10 μg/ml, 100 μl/well), as previously
described [17].
Evaluation of cellular PsaA-specific recall responses
Cytokine recall responses specific for PsaA were evalu-
ated using an enzyme linked immunospot (ELISPOT)
assay. This assay has been shown to be suitable for enu-
meration of low frequencies of antigen specific cellular
responses following in vivo priming with antigen [56].
Assays were performed essentially as described, with
minor modifications [56]. Briefly, plates (ImmunoSpot,
Resolution Technology, Columbus, OH) were coated
overnight at 4°C with the cytokine-specific capture Abs
specified below. The plates were blocked with 1% BSA
in PBS for 1 h at room temperature and washed four
times with PBS. Subsequently, freshly isolated spleen
cells from groups of mice primed with PsaA, PsaA +
BLyS, PsaA-BLyS fusion protein, or PsaA in complete
Freund’s adjuvant, and boosted with PsaA in PBS were
plated at 1 × 10
6 per well in flat-bottom, 96-well micro-
titer plates in serum-free HL-1 medium (BioWhittaker,
Walkersville, MD) supplemented with L-glutamine at
1 mM, in the presence or absence of recombinant PsaA.
After 24 or 48 h of cell culture in the incubator, the
cells were removed by washing three times with PBS
and four times with PBS containing 0.05% Tween
(PBST). Detection Abs were added and incubated at 4°C
overnight (either horse radish peroxidase (HRP)-labeled
or biotinylated). The plates were washed three times
with PBST. For biotinylated detection mAbs, streptavi-
din-HRP (Dako, Carpenteria, CA) was added at 1:3000
dilution, incubated for 2 h at room temperature, and
removed by washing twice with PBST and twice with
PBS. The spots were visualized by adding HRP substrate
3-amino-9-ethylcarbozole (Pierce, Rockford, IL). The
following combinations of capture and detection mAbs
were used for IL-2, IL-4, IL-5, and IFN-g assays respec-
tively: JES6-1A12 (5 μg/ml) and JES6-5H4-biotin (2 μg/
ml), BVD4-1D11 (2 μg/ml) and BVD4-24G2-biotin
(2.5 μg/ml), TRFK5 (5 μg/ml) and TRFK4-HRP (2 μg/
ml), and R46A2 (5 μg/ml) and XMG1.2-HRP (2 μg/ml).
Image analysis of ELISA spot assays was performed on a
Series 1 ImmunoSpot Image Analyzer (Resolution Tech-
nology, Columbus, OH) customized for analyzing ELISA
spots to meet objective criteria for size, chromatic den-
sity, shape, and color. Detection of PsaA-specific anti-
body secreting cells (ASC) was assessed for splenocytes
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ELISPOT assay described above. Briefly, plates were
coated with PsaA in place of cytokine capture antibo-
dies, and splenocytes were added to wells, as above. Fol-
lowing incubation, detection of total PsaA-specific ASC
was effected by incubation of washed wells with HRP-
conjugated anti-mouse Ig, followed by spot develop-
ment with 3-amino-9-ethylcarbozole.
Reviewers’ comments
Reviewer 1: Jonathan Yewdell, National Institute of
Allergy and Infectious Diseases, Laboratory of Viral
Diseases
Immunogenicity, the ability of a substance to elicit an
immune response, is the difference between a vaccine
protecting an individual against a given infectious dis-
ease vs. the individual suffering the consequences of
infection. There are two elements to immunogenicity.
One is the antigen itself. The antigen must be given in a
form that elicits the right type of adaptive immune
response, which is some combination of antibodies (pro-
duced by B cells) and T cells. The other element is the
adjuvant, which activates elements of the innate immune
system to in turn license B and T cells to become
activated.
The need for adjuvants (Charlie Janeway’sf a m o u s
Dirty Little Secret (1)) to induce effective immunity to
most non-infectious antigens (infectious agents typically
have considerable adjuvant activity of their own) is
probably the greatest stumbling block to improving vac-
cines to infectious diseases. A significant number of
individuals simply don’t respond to many vaccines, a
problem that is greatly exacerbated with age. Better
adjuvants would also allow use of lower doses of anti-
gen, saving money and potentially lives, when to cite a
cogent example, amounts of vaccine are limited and
Swine flu is on the march.
In the past, adjuvants were based on empirical obser-
vation of increased immunogenicity. Many of the best
adjuvants (e.g.c o m p l e t eF r e u n d ’s adjuvant, heat killed
mycobacteria emulsified in mineral oil) have such severe
side effects that their use is proscripted even in experi-
mental animal studies. There is but one FDA approved
adjuvant for use in humans, alum (alas).
After 30 years of basic research into the molecular
basis of immunity, the fruits are beginning to ripen, and
there is a wealth of information regarding the molecular
switches downstream of adjuvant activation of innate
immunity. Gor et al. focus on one such switch, the won-
derfully named BLyS (B lymphocyte stimulator),
expressed by immune cells to interact with receptors on
B and T lymphocytes. They convincingly show that con-
jugation of BLyS synthesized in bacteria to a medically
important antigen (pneumococcal surface adhesin A)
increases antibody responses, in a manner dependent on
o n eo ft h et h r e ek n o w nB L y Sr e ceptors, TACI. Intrigu-
ingly, the adjuvant effect of BLyS required covalent con-
jugation of BLyS to antigen (i.e. immunizing a mixture
of antigen plus BLyS did not enhance immunogenicity),
pointing the way to future studies on the processing and
presentation of antigen to B cells, a field with tremen-
dous opportunity for making basic discoveries, not to
mention additional studies on other antigens (e.g. flu
vaccine).
In summary, this is a fine study in an area of research,
immune adjuvant development, of great interest from
both basic and translational aspects. One of the most
telling findings is Figure 2, panel H, where the impress-
ive adjuvant effects of BLyS still fall far short of com-
plete Freund’s adjuvant, pointing to the need for
increased funding for adjuvant research.
1. Approaching the asymptote? Evolution and revo-
lution in immunology. Janeway, C.A.Jr. Cold Spring
Harb. Symp. Quant. Biol. 54, 1-13 (1989).
Author’s response
We thank the reviewer for his comments.
Reviewer 2: Michael Cancro, Department of Pathology
and Laboratory Medicine, University of Pennsylvania
School of Medicine (nominated by Andy Caton, Wistar
Institute)
The fusion protein is expressed as expected and the
fused BLyS retains biological activity, based on the viabi-
lity assays in Figure 1.
T h ed a t ai nF i g u r e2s h o wt h a tt h ef u s i o np r o t e i n
yields higher titres of PSA specific antibodies than
immunization with PSA alone or PSA with simulta-
neously administered free BLyS. These data also indicate
that no dsDNA-binding antibodies are generated upon a
brief BLyS or PSA-BLyS exposure. Accordingly, the cen-
tral idea may have merit, but questions remain regard-
ing the basis for and import of these enhanced titers.
First, it is not clear whether this reflects the biological
activity of BLyS-BLyS receptor interactions in promoting
B cell survival/activation per se, or instead represents a
“carrier” effect that enhances T cell activation, and does
not rely on BLyS’s native biological activity. The fusion
protein involved human BLyS with some linkers, and
will thus contain sequences that might be presented to
and recognized by mouse T cells, making this a plausi-
ble possibility. Since a carrier effect requires linked
recognition, treatment groups with simultaneous free
BLyS administration do not address this concern. A
number of approaches might be taken to address this,
but the most incisive might be a direct measure of
whether any T cells specific for human BLyS epitopes
are generated. This might be accomplished by a T cell
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with hBLyS plus T cells from the PSA-hBLyS primed
mice. Alternatively or in addition, one might construct
similar fusion proteins with either human BLyS that has
had its receptor-binding site disrupted, which should
not enhance; or with mouse BLyS, which should.
The second question arises upon noting that antibody
levels are enhanced about 5-fold over controls in most
of the primary immunizations. This increase is fairly
modest, and is dwarfed by the ~1000-fold differences
observed when CFA is used as an adjuvant. Thus, one
wonders what the absolute magnitude (on a weight per
volume basis) of the antibodies might be, and whether
the increases in titre would afford increased protection.
Accordingly, the paper would be strengthened by a fully
quantitative (mcg/ml) assessment of the serum antibody,
and by including some measure of whether the increases
with BLyS-PSA yield significant shifts in the infectivity
per se or in an in vitro surrogate for virulence/adhesion.
The results with the TACI deficient mice are intri-
guing, although they seem somewhat tangential to the
rest of the manuscript. While the observation is interest-
ing, additional experiments are required to assess their
import and relationship, if any, to the main thrust of the
article.
A minor point is the implication that the viability
assay used in Figure 1 necessarily reflects cell division.
This is unlikely in panel D of Figure 1, inasmuch as
BLyS alone does not induce cell division, but indeed fos-
ters survival in vitro. Assays directly discerning survival
and division, rather than just the relative number of
viable cells at the end of culture, would more directly
interrogate the biological activities of the fusion product
(e.g.; Flow cytometric analysis of CFSE plotted against
either TOPRO or DAPI). Nonetheless, the biological
activity of BLyS in the fusion protein indeed seems to
be preserved. This point is only made for precision.
Author’s response
We did consider the possibility, cited by the reviewer,
that the enhanced immune response to PsaA covalently
linked (versus not linked) to BLyS could have been due
to carrier function as opposed signalling through BLyS
receptors. While we agree that mutating the receptor-
binding site on BLyS would have been a valuable way to
address the importance of signalling through BLyS
receptors, when these studies were carried out, the
receptor-binding site on BLyS was not defined.
In support of the interpretation that the increased
immunogenicity of PsaA-BLyS versus PsaA alone or
PsaA + BLyS, TACI-deficient mice exhibited a smaller
increment than TACI-expressing mice in the antibody
response as a result of covalently linking BLyS to PsaA.
Since earlier work (von Bülow et al., 2001) and our own
studies established that TACI-deficient mice responded
normally to other typical protein (i.e., thymus-depen-
dent, or TD) antigens, we think it is unlikely that the
substantially decreased magnitude of the antibody
response to PsaA-BLyS of TACI -/- mice, in comparison
to TACI +/+ mice, is attributable to an effect of TACI-
deficiency on the T cell response. However, we acknowl-
edge that it would have been useful to assess the CD4
+
T-cell response to human BLyS in the mice immunized
with PsaA-BLyS.
We agree that quantitation of antibody responses in
mcg/ml is preferable when possible. When these studies
were performed there were few commercial reagents
available, and we did not have a monoclonal antibody
specific for BLyS to use in establishing the standard
curve required for such quantitation.
The results with the TACI-deficient mice are not tan-
gential in our view. Since as noted, above, TACI-defi-
cient mice responded normally to other typical protein
(i.e., thymus-dependent, or TD) antigens (KLH and
diphtheria toxoid; also see von Bülow et al., 2001), we
believed it was relevant that TACI -/- mice exhibited a
reduced response to PsaA-BLyS, relative to TACI +/+
mice. This result argues against BLyS functioning purely
as a carrier protein, since if TACI-deficiency substan-
tially reduced the responses of CD4
+ Tc e l l s ,t h e nw e
and others (von Bulow et al., 2001) should not have
found that TACI -/- mice generated antibody responses
to various protein immunogens comparably to TACI
+/+ mice. We do agree with the reviewer that there are
other aspects of the role of TACI that would require
further experiments.
The figure legend has been modified to reflect the
reviewer’s insight, which is appreciated.
Reviewer 3: Rachel Gerstein, Department of Microbiology
and Physiological Systems, University of Massachusetts
Medical School
PsaA is a protein antigen from Streptococcus pneumo-
niae. Efforts to generate a potent vaccine for S.p. that
protects independent of capsule antigen serotype have
not succeeded. Since the serotype is determined by the
capsular polysaccharide, investigation of protein antigens
from S.p. is important. Also, a serious limitation for vac-
cines are the adjuvants available for use in humans; the
most potent known adjuvants used in animal models
cause side-effects, and so new adjuvants that are both
effective and safe for use in humans are needed.
It would be helpful to state in more detail the ratio-
nale for using PsaA as a model antigen.
BLyS is an essential cytokine that controls B cell
development and homeostasis. The authors made a
fusion protein, PsaA-hBLyS, which is readily expressed
in E. coli and purified. When cultured with mouse sple-
nocytes, more cells are recovered when compared to
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μ to stimulate B cell proliferation. It is clear from the
literature that BLyS promotes increased B cell viability
and/or prevents apoptosis, so the experiment shows that
the fusion has the activity expected for bio-active BLyS
on mouse B cells.
PsaA-specific antibody responses in mice were deter-
mined using ELISA.
Importantly, anti-DNA abs are not detected (BLyS
over-expression in vivo leads to lupus and other autoim-
mune manifestations). Particularly impressive are the
levels of specific Ag when the secondary response is
measured - much higher than when PsaA + BLyS is
given as separate molecules in priming. Interestingly,
PsaA alone can boost if PsaA-BlyS OR PsaA + BLyS is
given in the primary. The authors discuss potential
mechanisms behind this observation.
One goal of the study was to consider this fusion sys-
tem as an adjuvant strategy - in this regard, when PsaA-
BLyS was compared to PsaA+CFA, CFA was the most
potent but PsaA-BLyS is better than PsaA+CpG
(another adjuvant that can promote antibody formation),
so the BLyS conjugate does have activity as an adjuvant.
In Figure 3, the broad IgG subclass distribution of the
response to PsaA-BLyS is documented. Also in Figure 3,
ASC are measured 1 week after boost (in spleen) and
very few are detected. Although not central to the
paper, the authors might consider using the same time
points after boost as the ELISA data and also examining
the bone marrow, a major repository of ASC.
In Figure 4, TACI-deficient mice are compared to WT
and heterozygous deficient mice. Interestingly, when
mice are immunized using PsaA-BLyS and boosted with
PsaA, the TACI KO do not respond well when either
primary or secondary responses are measured. The
interpretation and discussion of this result are thought
provoking, given that the major defect previously noted
in TACI-deficient mice is in responses to TI-2 antigens,
and PsaA is assumed to be a TD antigen. Given the
documented role of BLyS in augmenting TI responses, it
seems worth considering as to whether there is a
TI-component to the PsaA-BLyS response.
Overall, the Ms reports data that will be of interest to
immunologists and vaccinologists. The experiments are
done with appropriate rigor and reveal a potent affect
for boosting specific antibody responses without resort-
ing to problematic strong adjuvants.
Author’s response
We have added text to the Background section (p. 6)
addressing the rationale for using PsaA as a model
antigen.
The reviewer has made the excellent point that the
effect of BLyS is increased cell viability and not prolif-
eration. We have altered the figure legend to indicate
that this is a viability/proliferation assay. In the Materi-
a l sa n dM e t h o d ss e c t i o n( ”In vitro assay for BLyS
bioactivity”), we have described the Alamar Blue assay
which was used to assess increased cell numbers,
whether due to proliferation (as in anti IgM treated cul-
tures) or to increased viability (as in cultures containing
recombinant BLyS).
We have added material to the Discussion section on
the ability of PsaA alone to boost if PsaA-BlyS or PsaA
+ BLyS is given in the primary.
With reference to cytokines measured, we used an
ELISPOT assay. The numbers of cytokine secreting
spots are not very high using this assay, even for mice
immunized with CFA, but they are clearly elevated for
PsaA-BLyS compared to PsaA or PsaA + BLyS primed
mice. In subsequent studies, we might increase the
number of immunizations administered prior to assess-
ment of cellular responses to accentuate any possible
differences between groups that are reflected in the anti-
body production data.
We have changed the text in the abstract and
throughout to reflect the very modest but consistent
IFN-g production observed.
The reviewer has also made very reasonable points
about using matching time points for the cellular and
humoral responses, as well as including an assessment
of ASC in the bone marrow to obtain a more complete
picture of the responses elicited, and we concur.
To address the insightful comments by the reviewer,
we would like to briefly revisit some of our experimental
observations and the assumptions underpinning our
interpretation and presentation of the data.
We did not perform specific experiments to determine
whether the PsaA-BLyS response is a T cell dependent
(TD) response in the classical sense, in that we have not
performed immunization experiments using CD4
+ T
cell-deficient mice. Rather, we proceeded with the calcu-
lated assumption that PsaA is a TD antigen. This is sup-
ported by circumstantial observations such as the lack of
repeating motifs in the primary amino acid sequence for
PsaA, the monomeric nature of the recombinant protein
(as determined by migration patterns through non redu-
cing/non denaturing polyacrylamide gel electrophoresis),
the non-immunogenicity of PsaA in the absence of adju-
vants in both BALB/c and C3H/HeJ mouse strains, and
the ability to elicit elevated secondary antibody
responses dominated by the IgG subclasses other than
IgG3, following primary immunization with standard
adjuvants (CFA, IFA). These features are not character-
istic of TI antigens.
Perhaps we have inadvertently converted it (PsaA) to a
TI antigen by fusion to BLyS. Indeed one (we) should
not be surprised if some aspects of the immune
response resemble those elicited in response to classical
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BLyS receptors, TACI is required for responses to TI
antigens. However, unlike classical TI antigens (e.g.
polysaccharides), which never had the capacity to elicit
classical T cell help via MHC restricted antigen presen-
tation, peptides derived from PsaA in the PsaA-BLyS
fusion should still retain this capacity, and should there-
fore be influenced by the immunological mechanisms
involved in TD responses, such as the involvement of
DC in the priming of the immune response. If PsaA-
BLyS is indeed a TI antigen, we would still have to
explain other features of the Ig response elicited by it,
such as the boostability of the response, which is not
observed with classical TI antigens like polysaccharides,
but is a hallmark of TD responses. Additional indirect
support for our assumption that T cells are critical to
t h ei m m u n er e s p o n s et oP s a A ,w h e t h e rf u s e dt oB L y S
or not, comes from the recent finding that polymerized
bacterial flagellin, a protein which was long held to be a
T-independent antigen has instead been found to be a T
dependent antigen (C.J. Sanders, Y. Yu, D.A. Moore,
3rd, I.R. Williams, and A.T. Gewirtz, Humoral immune
response to flagellin requires T cells and activation of
innate immunity. J Immunol 177 (2006) 2810-18; PMID
16920916).
For these reasons, we feel that the discussion of TACI
expression on DC is pertinent because it would be sur-
prising (and very possibly a first, since flagellin should
n o wb ec o n s i d e r e daT Da n t i g e n )i ft h e r ew e r en oc o n -
tribution of T cells to the response to an exogenous
protein antigen (PsaA-BLyS). Although CD4
+ Tc e l l
help for antibody responses to some viral antigens may
be minimal, these antigens differ from PsaA-BLyS in
that they are primarily endogenously synthesized and
largely presented on MHC class I.
It would also be equally surprising if B cells were
found to be the primary APC responsible for initiating
the PsaA-BLyS response. Th i si su n d e r s c o r e db yt h e
observation that one of the mechanisms for inducing
tolerance to antigens is to exploit Ag presentation by B
cells, both activated and non-activated.
In this regard, our discussion of TACI expression by
DC represents the more conservative viewpoint (namely
that DC are the primary APC for productive responses
to TD antigens, and that virtually all proteins that have
been studied to date thus far are invariably TD
antigens).
We did not mention the role of TACI in class switch-
ing in the interest of focusing more directly on the
observation that there was no PsaA-specific antibody eli-
cited in response to PsaA-BLyS immunization in the
absence of TACI. We certainly appreciate the reported
role of TACI in immunoglobulin class switching but we
did not perform any specific experiments to address this
in our current studies. We do however now mention in
the Discussion (p. 23) that BLyS mediates class switch-
ing, and the corresponding reference cited specifically
states that TACI and BAFF-R are involved in antibody
isotype switching.
In summary, we acknowledge that the answer to the
TD/TI nature of the response to PsaA-BLyS is an
important issue, but we will have to address it in future
studies. Because we are prepared for the possibility that
both TI and TD mechanisms are involved in the
response to PsaA-BLyS, experiments using T cell defi-
cient mice (to study the TI question) would have to be
carried out in conjunction with experiments using ani-
mals with defects in pathways known to affect TD
responses (CD40-CD40L axis, OX40-OX40L axis, etc.),
as well as a robust means to compare the responses eli-
cited across the various experimental cohorts in order
to obtain satisfactory resolution to this question.
Yes indeed. We have stated in the Discussion that
unambiguous instances of B cells being able to prime
n a ï v eTc e l l sf o rap r o d u c t i v ei m m u n er e s p o n s ea r e
rare. The role of B cells in the BLyS-mediated response
(other than producing antibodies) can only be addressed
meaningfully after further experimentation to define the
APC involved, the TD vs. TI nature of the response, etc.
We have deleted the last paragraph from the conclu-
sion, as we have not supplied experimental data on
BLyS-mediated enhancement of responses to TI anti-
gens, and to avoid confusion.
We appreciate the positive comments on the manu-
script and also appreciate the highly insightful observa-
tions and questions posed in this review.
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